Trademark: 79302096
Word
PREVENTIS
Status
Registered
Status Code
700
Status Date
Tuesday, March 29, 2022
Serial Number
79302096
Registration Number
6681425
Registration Date
Tuesday, March 29, 2022
Mark Type
4000
Filing Date
Friday, December 4, 2020
Published for Opposition
Tuesday, January 11, 2022

Trademark Owner History
Immundiagnostik AG - Original Registrant

Classifications
5 diagnostic and analytical means for medical purposes in particular chemical preparations for use in disease prevention, namely, for detecting and preventing infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; chemical preparations for use in medical and pharmaceutical detection kits, namely, for detecting infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; chemicals for medical diagnostics and analysis relating to infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces; gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; all the aforesaid goods not for veterinary use; chemicals for medical diagnostics and analysis in the nature of chemical preparations for rapid testing of infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine

Trademark Events
Nov 30, 2023
International Registration Renewed
Sep 11, 2022
Final Decision Transaction Processed By Ib
Aug 19, 2022
Final Disposition Notice Sent To Ib
Aug 19, 2022
Final Disposition Processed
Jun 29, 2022
Final Disposition Notice Created, To Be Sent To Ib
Mar 29, 2022
Registered-Principal Register
Jan 11, 2022
Official Gazette Publication Confirmation E-Mailed
Jan 11, 2022
Published For Opposition
Jan 10, 2022
Notification Processed By Ib
Dec 22, 2021
Notification Of Possible Opposition Sent To Ib
Dec 22, 2021
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Dec 22, 2021
Notification Of Notice Of Publication E-Mailed
Dec 9, 2021
Approved For Pub - Principal Register
Dec 9, 2021
Examiner's Amendment Entered
Dec 9, 2021
Notification Of Examiners Amendment E-Mailed
Dec 9, 2021
Examiners Amendment E-Mailed
Dec 9, 2021
Examiners Amendment -Written
Nov 22, 2021
Teas/Email Correspondence Entered
Nov 22, 2021
Correspondence Received In Law Office
Nov 22, 2021
Teas Response To Office Action Received
Jun 13, 2021
Refusal Processed By Ib
May 21, 2021
Non-Final Action Mailed - Refusal Sent To Ib
May 21, 2021
Refusal Processed By Mpu
May 20, 2021
Non-Final Action (Ib Refusal) Prepared For Review
May 19, 2021
Non-Final Action Written
May 14, 2021
Assigned To Examiner
Jan 26, 2021
Application Filing Receipt Mailed
Jan 21, 2021
New Application Office Supplied Data Entered
Jan 19, 2021
Limitation From Original Application Entered
Jan 7, 2021
Sn Assigned For Sect 66a Subseq Desig From Ib

Trademark Alertz updated from USPTO on 2030-01-24